Article Text

Download PDFPDF
Inhaled corticosteroids were safely stepped down in chronic, stable asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with chronic, stable asthma, can the dosage of inhaled corticosteroids be safely stepped down?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Respirology ★★★★★☆☆


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

clinicians, patients, {data collectors, outcome assessors, data analysts, and monitoring committee}.*

Embedded ImageFollow up period:

12 month follow up at 3 month intervals.

Embedded ImageSetting:

general practices in western and central Scotland, UK.

Embedded ImagePatients:

259 patients ⩾18 years of age (mean age 54 y, 58% women), who had been diagnosed with asthma for ⩾1 year and were receiving ⩾800 μg daily of inhaled beclomethasone dipropionate (or equivalent dosage of budesonide or fluticasone propionate). Exclusion criteria: need for oral corticosteroids, general practice visit or hospital visit for asthma in the past 2 months; inability to use a peak flow metre; treatment with immunosuppressive drugs; serious illness; alcohol, drug, or substance abuse; …

View Full Text


  • * See glossary.

  • Information provided by author.

  • Abstract and commentary also appear in ACP Journal Club.

  • For correspondence: Dr N C Thomson, University of Glasgow, Glasgow, UK.

  • Sources of funding: NHS R&D Programme on Asthma Management. GlaxoSmithKline supplied the study inhalers.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd